Letters to the Editor
Vol. 9 No. 1 (2017): Review, Original Articles, Case Reports
https://doi.org/10.4084/mjhid.2017.012

Defining invasive fungal infection risk in hematological malignancies: a new tool for clinical practice

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: November 16, 2016
Accepted: December 9, 2016
Published: January 1, 2017
4035
Views
1153
Downloads
1548
HTML
Fungal infection, neutropenia, leukemia, lymphoma
Hematology, Infectious Disease

Authors

Benedetta Rambaldi
detta.rambaldi@hotmail.it
Cattedra di Ematologia, Unità di Malattie del Sangue e Trapianto di Midollo Osseo, Dipartimento di Scienze Cliniche e Sperimentali, Università di Brescia e ASST Spedali Civili, Brescia, Italy, Italy.
Domenico Russo
Cattedra di Ematologia, Unità di Malattie del Sangue e Trapianto di Midollo Osseo, Dipartimento di Scienze Cliniche e Sperimentali, Università di Brescia e ASST Spedali Civili, Brescia, Italy, Italy.
Livio Pagano
Istituto di Ematologia, Università Cattolica S. Cuore, Roma, Italy, Italy.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Pagano L, Akova M, Dimopoulos G, Herbrecht R, Drgona L, Blijlevens N. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. Journal of Antimicrobial Chemotherapy 2011: 66: i5-i14. http://jac.oxfordjournals.org/content/66/suppl_1/i5.abstract
Herbrecht R, Bories P, Moulin J-C, Ledoux M-P, Letscher-Bru Vr. Risk stratification for invasive aspergillosis in immunocompromised patients. Annals of the New York Academy of Sciences 2012:1272: 23-30. http://dx.doi.org/10.1111/j.1749-6632.2012.06829.x
Ananda-Rajah MR, Cheng A, Morrissey CO, et al. Attributable Hospital Cost and Antifungal Treatment of Invasive Fungal Diseases in High-Risk Hematology Patients: an Economic Modeling Approach. Antimicrobial Agents and Chemotherapy 201: 55: 1953-1960. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3088208/
Heimann SM, Vehreschild MJGT, Cornely OA, et al. A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation. European Journal of Haematology 2015: 94: 526-531. http://dx.doi.org/10.1111/ejh.12466
Pagano L, Busca A, Candoni A, et al. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Reviews 2016. http://www.sciencedirect.com/science/article/pii/S0268960X16300753

Ethics Approval

Letter to the Editor

How to Cite



“Defining invasive fungal infection risk in hematological malignancies: a new tool for clinical practice” (2017) Mediterranean Journal of Hematology and Infectious Diseases, 9(1), p. e2017012. doi:10.4084/mjhid.2017.012.